Amgen: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Amgen as lead sponsor. 1 are open to participants now and 13 have results posted.

Phase 1 5Phase 2 8Phase 3 4Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaNot yet recruitingNCT07223190Phase 3
• Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALLCompletedNCT04524455Phase 1Results posted
• Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04506086Phase 4Results posted
• Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Phase 3Results posted
• Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaCompletedNCT02412306Phase 1/2Results posted
• Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT02393859Phase 3Results posted
• Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02303821Phase 1Results posted
• Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT02013167Phase 3Results posted
• Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaCompletedNCT02000427Phase 2Results posted
• Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaCompletedNCT01471782Phase 1/2Results posted
• Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01466179Phase 2Results posted
• Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01209286Phase 2Results posted
• Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01207388Phase 2Results posted
• Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT00560794Phase 2Results posted
• A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Phase 1/2
• An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the USCompletedNCT02783651
• Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)CompletedNCT02303522
• Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia PatientsCompletedNCT02010931
• Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic LeukemiaCompletedNCT02003612